“It is difficult to predict whether access to mifepristone would be restricted immediately or more slowly should the court rule against the FDA,” said Susan J. Frietsche, co-executive director of Women’s Law Project.
“It is difficult to predict whether access to mifepristone would be restricted immediately or more slowly should the court rule against the FDA,” said Susan J. Frietsche, co-executive director of Women’s Law Project.
We'll send a verification code to %EMAIL%.